3/24
02:47 pm
plx
Protalix Revenue Miss Overshadowed By Milestone-Backed 2026 Guidance [Seeking Alpha]
Low
Report
Protalix Revenue Miss Overshadowed By Milestone-Backed 2026 Guidance [Seeking Alpha]
3/19
08:22 am
plx
Protalix BioTherapeutics (PLX) had its "buy" rating reaffirmed by HC Wainwright. They now have a $12.00 price target on the stock.
Low
Report
Protalix BioTherapeutics (PLX) had its "buy" rating reaffirmed by HC Wainwright. They now have a $12.00 price target on the stock.
3/18
03:08 pm
plx
Protalix BioTherapeutics Inc (PLX) Q4 2025 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]
Low
Report
Protalix BioTherapeutics Inc (PLX) Q4 2025 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]
3/18
09:18 am
plx
Protalix BioTherapeutics advances Fabry disease and gout programs during 2025 [Yahoo! Finance]
Medium
Report
Protalix BioTherapeutics advances Fabry disease and gout programs during 2025 [Yahoo! Finance]
3/18
06:50 am
plx
Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results
High
Report
Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results
3/17
03:33 pm
plx
Protalix BioTherapeutics FY Earnings Preview [Seeking Alpha]
Low
Report
Protalix BioTherapeutics FY Earnings Preview [Seeking Alpha]
3/11
06:50 am
plx
Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026
Low
Report
Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026
3/10
06:43 am
plx
Protalix BioTherapeutics and partner secure EU approval for new Fabry disease dosing regimen [Yahoo! Finance]
Low
Report
Protalix BioTherapeutics and partner secure EU approval for new Fabry disease dosing regimen [Yahoo! Finance]
3/9
06:15 am
plx
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) [Yahoo! Finance]
High
Report
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) [Yahoo! Finance]
3/9
06:00 am
plx
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)
High
Report
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)
1/30
09:47 am
plx
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU
High
Report
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU
1/5
06:50 am
plx
Protalix BioTherapeutics Letter to Stockholders
Low
Report
Protalix BioTherapeutics Letter to Stockholders